Welcome!

News Feed Item

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics

https://www.reportbuyer.com/product/2225949/Licensing-Terms-and-Agreements-in-Pharma-Biotech-and-Diagnostics.html

The Licensing Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why companies enter licensing deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of licensing dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where licensing forms a part.

Chapter 4 provides a review of the leading licensing deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, signed by bigbiotech, most active bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive review of licensing financials for deals announced since 2009, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

Chapters 6 and 7 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of licensing deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of licensing deals signed and announced since 2009 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing dealmaking, enabling thorough learning, education and due diligence prior and during the licensing dealmaking process.

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in licensing dealmaking

2.1. Introduction
2.2. Definition of licensing deals
2.3. Success factors for licensing deals
2.4. When licensing can be useful
2.5. Attributes of licensing deals
2.6. Trends in licensing deals since 2009
2.7. Option to license
2.8. Adding co-promotion to the mix
2.9. The future of licensing deals

Chapter 3 – Overview of licensing deal structure

3.1. Introduction
3.2. Pure versus multi-component licensing deals
3.3. Pure licensing agreement structure
3.3.1. Example licensing agreements
3.3.1.a. Case study 1: Ignyta – Nerviano Medical Sciences – November 2013
3.3.1.b. Case study 2: Sanofi - Pozen – September 2013
3.4. Licensing rights as part of a wider alliance agreement
3.4.1. Example licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics – UniQure – January 2014
3.4.1.b. Case study 4: Kyowa Hakko Kirin – Ultragenyx Pharmaceuticals – September 2013
3.4.2. Example licensing option right clauses
3.4.2.a. Case study 5: Forest Laboratories - Trevena – May 2013
3.4.2.b. Case study 6: Abbvie – Receptos – March 2013

Chapter 4 – Leading licensing deals

4.1. Introduction
4.2. Top licensing deals by value
4.3. Most active licensing dealmakers
4.3.1 Most active licensing dealmakers by therapy
4.3.2. Most active licensing dealmaker by stage of development
4.4. Bigpharma licensing deal activity
4.4. Bigbiotech licensing deal activity

Chapter 5 – Licensing deal term benchmarks

5.1. Introduction
5.2.1. Licensing headline values
5.2.2. Licensing upfront payments
5.2.3. Licensing milestone payments
5.2.4. Licensing royalty rates

Chapter 6 – Bigpharma licensing deals

6.1. Introduction
6.2. How to use licensing deals
6.3. Company licensing agreement listings

Chapter 7 – Bigbiotech licensing deals

7.1. Introduction
7.2. How to use licensing deals
7.3. Company licensing agreement listings

Chapter 8 – Licensing contract directory 2009-2014

8.1. Introduction
8.2. Company A-Z

Appendices

Appendix 1 – Licensing dealmaking - by financial disclosure
Appendix 2 – Licensing dealmaking - by companies A-Z
Appendix 3 – Licensing dealmaking - by stage of development
Appendix 4 – Licensing dealmaking - by therapeutic target
Appendix 5 – Licensing dealmaking - by technology type

Table of figures

Figure 1: Definition of licensing
Figure 2: Situations where licensing can prove useful
Figure 3: Key attributes of a licensing deal
Figure 4: Trends in licensing deal announcements, 2009-2014
Figure 5: Licensing deals signed at each phase of development, 2009-2014
Figure 6: Licensing deals by therapy area, 2009-2014
Figure 7: Licensing agreements – what should a contract include?
Figure 8: Components of the licensing deal structure
Figure 9: Top licensing deals by value since 2009 exceeding $1bn
Figure 10: Most active licensing dealmakers 2009-2014
Figure 11: Most active licensing dealmakers 2009-2014 by therapy area
Figure 12: Most active licensing dealmakers 2009-2014 – by stage of development
Figure 13: Bigpharma – top 50 – licensing deals 2009 to 2014
Figure 14: Bigpharma licensing deal frequency - 2009 to 2014
Figure 15: Bigbiotech – top 50 – licensing deals 2009 to 2014
Figure 16: Bigbiotech licensing deal frequency - 2009 to 2014
Figure 17: Licensing deal headline value distribution, US$million – discovery stage
Figure 18: Licensing deal headline value distribution, US$million – preclinical stage
Figure 19: Licensing deal headline value distribution, US$million – phase I stage
Figure 20: Licensing deal headline value distribution, US$million – phase II stage
Figure 21: Licensing deal headline value distribution, US$million – phase III stage
Figure 22: Licensing deal headline value distribution, US$million – regulatory stage
Figure 23: Licensing deal headline value distribution, US$million – marketed stage
Figure 24: Summary median licensing headline value by stage of development, 2009-2014
Figure 25: Licensing deal upfront payment distribution, US$million – discovery stage
Figure 26: Licensing deal upfront payment distribution, US$million – preclinical stage
Figure 27: Licensing deal upfront payment distribution, US$million – phase I stage
Figure 28: Licensing deal upfront payment distribution, US$million – phase II stage
Figure 29: Licensing deal upfront payment distribution, US$million – phase III stage
Figure 30: Licensing deal upfront payment distribution, US$million – regulatory stage
Figure 31: Licensing deal upfront payment distribution, US$million – marketed stage
Figure 32: Summary median licensing upfront payments by stage of development, 2009-2014
Figure 33: Licensing deal milestone distribution, US$million – discovery stage
Figure 34: Licensing deal milestone distribution, US$million – preclinical stage
Figure 35: Licensing deal milestone distribution, US$million – phase I stage
Figure 36: Licensing deal milestone distribution, US$million – phase II stage
Figure 37: Licensing deal milestone distribution, US$million – phase III stage
Figure 38: Licensing deal milestone distribution, US$million – regulatory stage
Figure 39: Licensing deal milestone distribution, US$million – marketed stage
Figure 40: Licensing deals with royalty rates, %
Figure 41: Licensing deal royalty rate distribution, US$million – discovery stage
Figure 42: Licensing deal royalty rate distribution, US$million – preclinical stage
Figure 43: Licensing deal royalty rate distribution, US$million – phase I stage
Figure 44: Licensing deal royalty rate distribution, US$million – phase II stage
Figure 45: Licensing deal royalty rate distribution, US$million – phase III stage
Figure 46: Licensing deal royalty rate distribution, US$million – regulatory stage
Figure 47: Licensing deal royalty rate distribution, US$million – marketed stage
Figure 48: Summary median licensing royalty rate by stage of development, 2009-2014
Figure 49: Online partnering resources
Figure 50: Deal type definitions

Read the full report:
Licensing Terms and Agreements in Pharma, Biotech and Diagnostics

https://www.reportbuyer.com/product/2225949/Licensing-Terms-and-Agreements-in-Pharma-Biotech-and-Diagnostics.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...
Verizon Communications Inc. (NYSE, Nasdaq: VZ) and Yahoo! Inc. (Nasdaq: YHOO) have entered into a definitive agreement under which Verizon will acquire Yahoo's operating business for approximately $4.83 billion in cash, subject to customary closing adjustments. Yahoo informs, connects and entertains a global audience of more than 1 billion monthly active users** -- including 600 million monthly active mobile users*** through its search, communications and digital content products. Yahoo also co...
Ixia (Nasdaq: XXIA) has announced that NoviFlow Inc.has deployed IxNetwork® to validate the company’s designs and accelerate the delivery of its proven, reliable products. Based in Montréal, NoviFlow Inc. supports network carriers, hyperscale data center operators, and enterprises seeking greater network control and flexibility, network scalability, and the capacity to handle extremely large numbers of flows, while maintaining maximum network performance. To meet these requirements, NoviFlow in...
As companies gain momentum, the need to maintain high quality products can outstrip their development team’s bandwidth for QA. Building out a large QA team (whether in-house or outsourced) can slow down development and significantly increases costs. This eBook takes QA profiles from 5 companies who successfully scaled up production without building a large QA team and includes: What to consider when choosing CI/CD tools How culture and communication can make or break implementation
"There's a growing demand from users for things to be faster. When you think about all the transactions or interactions users will have with your product and everything that is between those transactions and interactions - what drives us at Catchpoint Systems is the idea to measure that and to analyze it," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York Ci...
Redis is not only the fastest database, but it is the most popular among the new wave of databases running in containers. Redis speeds up just about every data interaction between your users or operational systems. In his session at 19th Cloud Expo, Dave Nielsen, Developer Advocate, Redis Labs, will share the functions and data structures used to solve everyday use cases that are driving Redis' popularity.
UpGuard has become a member of the Center for Internet Security (CIS), and will continue to help businesses expand visibility into their cyber risk by providing hardening benchmarks to all customers. By incorporating these benchmarks, UpGuard's CSTAR solution builds on its lead in providing the most complete assessment of both internal and external cyber risk. CIS benchmarks are a widely accepted set of hardening guidelines that have been publicly available for years. Numerous solutions exist t...
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Choosing the right cloud for your workloads is a balancing act that can cost your organization time, money and aggravation - unless you get it right the first time. Economics, speed, performance, accessibility, administrative needs and security all play a vital role in dictating your approach to the cloud. Without knowing the right questions to ask, you could wind up paying for capacity you'll never need or underestimating the resources required to run your applications.
SYS-CON Events announced today that LeaseWeb USA, a cloud Infrastructure-as-a-Service (IaaS) provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LeaseWeb is one of the world's largest hosting brands. The company helps customers define, develop and deploy IT infrastructure tailored to their exact business needs, by combining various kinds cloud solutions.
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
The competitive landscape of the global cloud computing market in the healthcare industry is crowded due to the presence of a large number of players. The large number of participants has led to the fragmented nature of the market. Some of the major players operating in the global cloud computing market in the healthcare industry are Cisco Systems Inc., Carestream Health Inc., Carecloud Corp., AGFA Healthcare, IBM Corp., Cleardata Networks, Merge Healthcare Inc., Microsoft Corp., Intel Corp., an...